

Ezetimibe therapy: mechanism of action and clinical up

Vascular Health and Risk Management
8, 415

DOI: [10.2147/vhrm.s33664](https://doi.org/10.2147/vhrm.s33664)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. <i>Future Cardiology</i> , 2012, 8, 813-817.	0.5	3
2	Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. <i>Lipids in Health and Disease</i> , 2012, 11, 123.	1.2	68
3	Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy. <i>Current Cardiology Reports</i> , 2013, 15, 397.	1.3	31
4	Clinical Relevance of Target Identity and Biology. <i>Journal of Biomolecular Screening</i> , 2013, 18, 1164-1185.	2.6	7
5	RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. <i>Lipids in Health and Disease</i> , 2013, 12, 142.	1.2	4
6	Cardiovascular disease: Prevention and treatment in renal transplant recipients. <i>Clinical Queries Nephrology</i> , 2013, 2, 184-196.	0.2	0
8	Pharmacogenomics of lipid-lowering therapies. <i>Pharmacogenomics</i> , 2013, 14, 981-995.	0.6	20
9	Decreased Endogenous Production of Hydrogen Sulfide Accelerates Atherosclerosis. <i>Circulation</i> , 2013, 127, 2523-2534.	1.6	322
10	An update on serum amyloid Aâ€œLDL and its potential use for dyslipidemic patients receiving lipid-modulating treatment. <i>Clinical Lipidology</i> , 2013, 8, 419-423.	0.4	0
11	The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. <i>Clinical Lipidology</i> , 2013, 8, 243-256.	0.4	2
12	Are add-on agents to statin therapy necessary in hypercholesterolemia?. <i>Clinical Lipidology</i> , 2014, 9, 695-707.	0.4	0
13	Cholesterol Treatment Patterns and Cardiovascular Clinical Outcomes Associated with Colesevelam HCl and Ezetimibe. <i>Drugs and Aging</i> , 2014, 31, 683-694.	1.3	4
14	Pharmacokinetics, pharmacodynamics, safety, and tolerability of hyzetimibe (HS-25) in healthy Chinese subjects. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1144-1152.	1.0	13
15	Inhibitors of Hepatitis B Virus Attachment and Entry. <i>Intervirolgy</i> , 2014, 57, 151-157.	1.2	60
16	Efficacy and safety of ezetimibe plus atorvastatin therapy. <i>Clinical Lipidology</i> , 2014, 9, 441-470.	0.4	7
17	LXR Driven Induction of HDLâ€œCholesterol is Independent of Intestinal Cholesterol Absorption and ABCA1 Protein Expression. <i>Lipids</i> , 2014, 49, 71-83.	0.7	16
18	Treatment of Cholesterol in the Elderly: Statins and Beyond. <i>Current Atherosclerosis Reports</i> , 2014, 16, 385.	2.0	8
20	Treatment of Dyslipidemia and Cardiovascular Outcomes: The Journey So Farâ€œIs This the End for Statins?. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 192-205.	2.3	20

#	ARTICLE	IF	CITATIONS
21	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. <i>American Heart Journal</i> , 2014, 168, 205-212.e1.	1.2	93
22	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 1724.	1.4	207
23	Modulation of Adhesion Molecules by Cholesterol-Lowering Therapy in Mononuclear Cells from Hypercholesterolemic Patients. <i>Cardiovascular Therapeutics</i> , 2015, 33, 168-176.	1.1	10
24	Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia. <i>Journal of Pediatrics</i> , 2015, 166, 1377-1384.e3.	0.9	56
25	A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus. <i>Lipids in Health and Disease</i> , 2015, 14, 37.	1.2	10
26	Statins and Ezetimibe. , 2015, , 25-36.		1
27	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statins and Newer Drugs. <i>Drugs</i> , 2015, 75, 1201-1228.	4.9	18
28	Physicochemical characterization and pharmacological evaluation of ezetimibe-PVP K30 solid dispersions in hyperlipidemic rats. <i>Colloids and Surfaces B: Biointerfaces</i> , 2015, 134, 423-430.	2.5	18
29	Using inactivating mutations to provide insight into drug action. <i>Genome Medicine</i> , 2015, 7, 7.	3.6	2
30	Common single nucleotide polymorphisms at the NPC1L1 gene locus significantly predict cardiovascular risk in coronary patients. <i>Atherosclerosis</i> , 2015, 242, 340-345.	0.4	14
31	Dyslipidemia in Obesity. , 2015, , 1-18.		1
32	Nicotinic acid and derivatives as multifunctional pharmacophores for medical applications. <i>European Food Research and Technology</i> , 2015, 240, 1-17.	1.6	47
33	Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 629-650.	1.4	72
34	Evaluation of the mRNA and Protein Expressions of Nutritional Biomarkers in the Gastrointestinal Mucosa of Patients with Small Intestinal Disorders. <i>Internal Medicine</i> , 2016, 55, 2145-2152.	0.3	1
35	The Role of Ezetimibe in the Treatment of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2016, 18, 8.	2.0	3
36	Chiral Separation and Thermodynamic Investigation of Ezetimibe Optical Isomers on a Chiralpak IC Column. <i>Journal of Chromatographic Science</i> , 2016, 54, 1489-1494.	0.7	9
37	Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1451-1465.	1.3	30
38	Dyslipidemia in Obesity. , 2016, , 525-540.		4

#	ARTICLE	IF	CITATIONS
39	Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes. Trends in Pharmacological Sciences, 2016, 37, 207-219.	4.0	12
40	Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opinion on Pharmacotherapy, 2016, 17, 369-380.	0.9	43
41	Ezetimibe: an update on its clinical usefulness in specific patient groups. Therapeutic Advances in Chronic Disease, 2017, 8, 4-11.	1.1	44
42	Why Prodrugs and Propeptides Succeed. Chemical Research in Toxicology, 2017, 30, 1117-1126.	1.7	30
44	Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. The Cochrane Library, 2017, , .	1.5	2
45	Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia. American Journal of Cardiovascular Drugs, 2017, 17, 169-181.	1.0	19
46	Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Postgraduate Medicine, 2017, 129, 801-810.	0.9	2
47	Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. Clinical Therapeutics, 2017, 39, 1799-1810.	1.1	12
48	Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles. Journal of Visualized Experiments, 2017, , .	0.2	1
49	Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs. Journal of Inflammation, 2017, 14, 3.	1.5	5
50	High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes. Current Cardiology Reviews, 2017, 13, 168-182.	0.6	9
51	The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes. Journal of Atherosclerosis and Thrombosis, 2017, 24, 735-748.	0.9	15
52	Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infectious Diseases, 2017, 17, 551.	1.3	112
53	Study on the HPLC-based separation of some ezetimibe stereoisomers and the underlying stereorecognition process. Chirality, 2018, 30, 642-651.	1.3	1
54	Large-scale computational drug repositioning to find treatments for rare diseases. Npj Systems Biology and Applications, 2018, 4, 13.	1.4	40
55	A consensus statement on lipid management after acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 532-543.	0.4	27
56	Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes. Journal of Evaluation in Clinical Practice, 2018, 24, 222-231.	0.9	7
57	Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nature Reviews Nephrology, 2018, 14, 57-70.	4.1	192

#	ARTICLE	IF	CITATIONS
58	Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. The Cochrane Library, 2018, 2018, CD012502.	1.5	53
59	Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus. Drugs in Context, 2018, 7, 1-7.	1.0	14
60	Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. Current Diabetes Reports, 2018, 18, 138.	1.7	4
61	Further options for treating lipids in people with diabetes: targeting <sc>LDL</sc> cholesterol and beyond. Diabetic Medicine, 2018, 35, 1173-1180.	1.2	3
62	Development of an LC-MS Method for 4-Fluoroaniline Determination in Ezetimibe. Journal of Chromatographic Science, 2018, 56, 724-730.	0.7	4
63	Pharmacological Targets for Correction of Dyslipidemias. Opportunities and Prospects of Therapeutic Use. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2018, 12, 96-113.	0.2	2
64	Combined spectroscopic and quantum chemical approach to study the effect of hydrogen bonding interactions in ezetimibe. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2019, 206, 246-253.	2.0	9
65	The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 54-61.	1.0	5
66	An update on pharmacotherapies in diabetic dyslipidemia. Progress in Cardiovascular Diseases, 2019, 62, 334-341.	1.6	24
67	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.4	1,753
68	Drug-drug interactions when treating HIV-related metabolic disorders. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 787-802.	1.5	6
69	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA. Journal of Medicinal Chemistry, 2019, 62, 6175-6189.	2.9	26
70	Current pharmacotherapies for atherosclerotic cardiovascular diseases. Archives of Pharmacal Research, 2019, 42, 206-223.	2.7	10
71	Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cellular Signalling, 2019, 55, 53-64.	1.7	23
72	Cholesterol Lowering and Prevention of Stroke. Stroke, 2019, 50, 537-541.	1.0	27
73	Drug Therapy of Dyslipidemia in the Elderly. Drugs and Aging, 2019, 36, 321-340.	1.3	22
74	ANGPTL3 Inhibitors – Their Role in Cardiovascular Disease Through Regulation of Lipid Metabolism. Circulation Journal, 2019, 83, 267-273.	0.7	26
75	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	1.0	4,871

#	ARTICLE	IF	CITATIONS
76	Comparison of Food and Nutrient Intakes between Japanese Dyslipidemic Patients with and without Low-Density Lipoprotein Cholesterol Lowering Drug Therapy: A Cross-Sectional Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 683-694.	0.9	3
77	Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses. <i>International Journal of Molecular Sciences</i> , 2020, 21, 232.	1.8	22
78	Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. <i>Lipids in Health and Disease</i> , 2020, 19, 1.	1.2	86
79	Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. <i>Atherosclerosis</i> , 2020, 313, 126-136.	0.4	52
80	Visceral Obesity and Its Shared Role in Cancer and Cardiovascular Disease: A Scoping Review of the Pathophysiology and Pharmacological Treatments. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9042.	1.8	29
81	Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2137-2151.	0.9	7
82	Clopidogrel drug interactions: a review of the evidence and clinical implications. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1079-1096.	1.5	8
83	Lipid lowering therapy in cardiovascular disease: From myth to molecular reality. , 2020, 213, 107592.		35
84	Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 361-379.	3.5	119
85	Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine</i> , 2020, 9, 1675.	1.0	1
86	New possible pharmacological targets for statins and ezetimibe. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110388.	2.5	35
87	Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 381-392.	1.0	29
88	Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. <i>Pharmacoeconomics</i> , 2020, 38, 1095-1113.	1.7	28
89	Metabolic Alterations in spinal and bulbar muscular atrophy. <i>Revue Neurologique</i> , 2020, 176, 780-787.	0.6	7
90	Liver Injury Associated With Ezetimibe Monotherapy. <i>CJC Open</i> , 2021, 3, 195-197.	0.7	4
91	Promoting cardiovascular health post-transplant through early diagnosis and adequate management of hypertension and dyslipidemia. <i>Pediatric Transplantation</i> , 2021, 25, e13811.	0.5	4
92	Drugs Used in Dyslipidemia. , 2021, , 505-529.		0
93	Ezetimibe. <i>Stroke Revisited</i> , 2021, , 91-101.	0.2	1

#	ARTICLE	IF	CITATIONS
94	Co-processing of Atorvastatin and Ezetimibe for Enhanced Dissolution Rate: In Vitro and In Vivo Correlation. <i>AAPS PharmSciTech</i> , 2021, 22, 59.	1.5	4
95	Impact on urinary oxalate levels with use of ezetimibe. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00221.	1.0	0
96	Novel Experimental Agents for the Treatment of Hypercholesterolemia. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 91-100.	1.5	14
97	Personalized medicine in lipid-modifying therapy. <i>Personalized Medicine</i> , 2021, 18, 185-203.	0.8	2
98	One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1. <i>European Journal of Medicinal Chemistry</i> , 2021, 216, 113358.	2.6	16
99	Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab. <i>Current Medicinal Chemistry</i> , 2021, 28, 1025-1041.	1.2	10
100	Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy. <i>Frontiers in Oncology</i> , 2021, 11, 682911.	1.3	56
101	Synthesis and Modeling of Ezetimibe Analogues. <i>Molecules</i> , 2021, 26, 3107.	1.7	6
102	Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 815-834.	0.6	11
103	A phenome-wide association study of genetically mimicked statins. <i>BMC Medicine</i> , 2021, 19, 151.	2.3	16
104	Bempedoic Acid: A New Non-statin Drug for the Treatment of Dyslipidemia. <i>Clinical Drug Investigation</i> , 2021, 41, 843-851.	1.1	5
105	Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes) <i>Tj ETQq b.30.7843l4 rgBT</i>		
106	Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 141-150.	1.3	4
107	Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapiesâ€™a Clinical Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1269-1279.	1.3	13
108	Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 183.	1.1	16
109	Poststatin Lipid Therapeutics: A Review. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 32.	0.5	8
110	Application of Multivariate Calibration Methods, in Dissolution Testing and Simultaneous Determination of Atorvastatin and Ezetimibe in Their Combined Solid Dosage Form. <i>Pharmaceutical Sciences</i> , 2016, 22, 105-111.	0.8	4
111	Ezetimibe Therapy for Dyslipidemia: An Update. <i>Current Pharmaceutical Design</i> , 2013, 19, 3107-3114.	0.9	40

#	ARTICLE	IF	CITATIONS
112	Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications. <i>World Journal of Hepatology</i> , 2016, 8, 924.	0.8	50
113	Stability indicating RP-UPLC method for simultaneous quantification of bempedoic acid and ezetimibe in bulk and pharmaceutical formulations. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, .	1.1	2
114	Homozygous Familial Hypercholesterolemia: Case report and Review of Literature. <i>American Journal of Internal Medicine</i> , 2014, 2, 34.	0.1	1
115	Correction of dyslipidemia in patients with ischemic heart disease and diabetes mellitus type 2. <i>LÃ-ki UkraÃ-ni</i> , 2016, .	0.0	0
118	Long-term hypocholesterolemic effect of amidated alginate in rats. <i>Ukrainian Biochemical Journal</i> , 2018, 90, 120-125.	0.1	0
119	Characterization, Purity Determination and Decomposition Kinetics of Ezetimibe Under Non-Isothermal Conditions. <i>Current Pharmaceutical Analysis</i> , 2019, 15, 327-332.	0.3	1
120	Strategy and tactics of treatment of type 2 diabetes mellitus. <i>Vnitri Lekarstvi</i> , 2019, 65, 273-278.	0.1	2
121	Ezetimibe in the treatment of hypercholesterolaemia. <i>Interni Medicina Pro Praxi</i> , 2019, 21, 112-116.	0.0	0
122	HYPOLIPIDEMIC EFFICACY OF ZINGIBER OFFICINALE EXTRACT IN COMPARISON WITH FENOFIBRATE, ROSUVASTATIN AND EZETIMIBE IN HYPERLIPIDEMIC RATS. <i>Journal of Sulaimani Medical College</i> , 2019, 9, 209-218.	0.0	2
123	Intestinally Active Therapies for Hypercholesterolemia: Ezetimibe, Bile Acid Resins, and Plant Sterols. <i>Contemporary Cardiology</i> , 2021, , 219-268.	0.0	0
124	Dyslipidemia in the Pediatric Population. , 2021, , 339-347.		0
125	Features of using of a fixed combination of rosuvastatin and ezetimibe for effective hypolipidemic therapy. <i>Meditinskiy Sovet</i> , 2020, , 26-32.	0.1	3
126	A case of abdominal pain with dyslipidemia: difficulties diagnosing cholesterol ester storage disease. <i>European Review for Medical and Pharmacological Sciences</i> , 2015, 19, 2628-2633.	0.5	4
127	The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus. <i>Metabolites</i> , 2021, 11, 807.	1.3	17
128	Shortening Synthetic Routes to Small Molecule Active Pharmaceutical Ingredients Employing Biocatalytic Methods. <i>Chemical Reviews</i> , 2022, 122, 1052-1126.	23.0	105
129	DyslipidÃmien: Aktuelles Lipid-Management. , 0, , .		0
130	Bone Health in Patients with Dyslipidemias: An Underestimated Aspect. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1639.	1.8	34
131	Nuclear Receptor PXR in Drug-Induced Hypercholesterolemia. <i>Cells</i> , 2022, 11, 313.	1.8	12

#	ARTICLE	IF	CITATIONS
132	Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption. <i>European Journal of Medicinal Chemistry</i> , 2022, 230, 114111.	2.6	27
133	Contemporary Management of Dyslipidemia. <i>Drugs</i> , 2022, 82, 559-576.	4.9	14
134	Investigating the effects of statins on ischemic heart disease allowing for effects on body mass index: a Mendelian randomization study. <i>Scientific Reports</i> , 2022, 12, 3478.	1.6	3
135	Studies of the Formation and Stability of Ezetimibe-Cyclodextrin Inclusion Complexes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 455.	1.8	5
136	Newly Invented Micellized Vitamin K2 Recovered Prolonged Prothrombin Time under Obstructive Jaundice in Rats with Bile Duct Ligation. <i>Journal of Nutritional Science and Vitaminology</i> , 2021, 67, 397-403.	0.2	0
138	Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations. <i>Pharmaceutics</i> , 2022, 14, 912.	2.0	4
139	Formulation and evaluation of selexipag and ezetimibe bi-layer tablet by novel approach. <i>International Journal of Health Sciences</i> , 0, , 3256-3275.	0.0	0
140	Targeted Strategy in Lipid-Lowering Therapy. <i>Biomedicines</i> , 2022, 10, 1090.	1.4	19
141	Synchronized analysis of bempedoic acid and ezetimibe in pure binary mixture and their combined tablets by a new stability indicating RP-UPLC method. <i>International Journal of Health Sciences</i> , 0, , 7278-7290.	0.0	0
142	Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. <i>Expert Review of Cardiovascular Therapy</i> , 0, , 1-13.	0.6	1
143	Lipid-Lowering Therapy in Women of Childbearing Age: a Review and Stepwise Clinical Approach. <i>Current Cardiology Reports</i> , 2022, 24, 1373-1385.	1.3	1
144	Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	78
145	The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia. <i>Current Cardiology Reports</i> , 2022, 24, 1669-1677.	1.3	5
146	Recent Advances on the Roles of PCSK-9 Inhibitors in the Management of Acute Ischemic Stroke Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10221.	1.8	2
147	Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2022, 12, e061884.	0.8	0
148	Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review. <i>Cureus</i> , 2022, , .	0.2	1
149	An Efficient, Simultaneous Electrochemical Assay of Rosuvastatin and Ezetimibe from Human Urine and Serum Samples. <i>Methods and Protocols</i> , 2022, 5, 90.	0.9	2
150	FORMULATION AND EVALUATION OF COCRYSTALS OF A BCS CLASS II DRUG USING GLYCINE AS COFORMER. <i>International Journal of Applied Pharmaceutics</i> , 0, , 68-76.	0.3	0

#	ARTICLE	IF	CITATIONS
151	Perfluoroalkyl Substance Serum Concentrations and Cholesterol Absorption-Inhibiting Medication Ezetimibe. <i>Toxics</i> , 2022, 10, 799.	1.6	2
152	Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?. <i>American Journal of Preventive Cardiology</i> , 2023, 13, 100451.	1.3	1
153	Inclisiranâ€”A Revolutionary Addition to a Cholesterol-Lowering Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6858.	1.8	3
154	Efficacy and Safety of Coadministered Ezetimibeâ€”Rosuvastatin plus Telmisartan in South Korean Patients with Dyslipidemia and Hypertension: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase III Trial. <i>Journal of Clinical Medicine</i> , 2023, 12, 2377.	1.0	1
155	Atherosclerosis: The Involvement of Immunity, Cytokines and Cells in Pathogenesis, and Potential Novel Therapeutics. , 2022, .		2
156	A Bioequivalence Study of Ezetimibe/Rosuvastatin Fixed Dose Combination (10Âmg/10Âmg) Versus the Individual Formulations Taken Concomitantly. <i>Advances in Therapy</i> , 0, , .	1.3	0